Several of the events took place at ‘upscale restaurants’ in San Francisco, at costs of up to $163 per person, according to ...

Attorney General Dave Sunday announced that Pennsylvania will receive over $1 million as part of a $202 million multistate ...

He made a conceptual leap in immunotherapy by creating a hybrid T-cell, known as CAR-T, that was genetically modified to ...

Headquartered in Foster City, California, Gilead Sciences, Inc. (GILD) is a global biopharmaceutical leader committed to ...

Gilead's Papao shares insights on the evolving role of public-private collaboration in healthcare, and how emerging tech is ...

HIV pharma leaders are in Kigali, Rwanda for IAS 2025, touting their latest advancements in HIV and PrEP development on the ...

The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV ...

Gilead, Global Fund Finalize Plan to Supply HIV Prevention Drug to Poor Countries By Deena Beasley and Jennifer Rigby (Reuters) -Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and ...

Gilead Sciences Inc. closed 9.09% short of its 52-week high of $119.96, which the company achieved on March 10th.

Gilead Sciences (GILD) closed at $110.17 in the latest trading session, marking a +1.75% move from the prior day. This change outpaced the S&P 500's 0.06% gain on the day. On the other hand, the Dow ...

The World Health Organization (WHO) has included Gilead Sciences' twice-yearly formulation of lenacapavir for pre-exposure ...

State attorneys general and federal prosecutors alleged Gilead Sciences illegally bankrolled lavish events for prescribers.